Adenocarcinomas News and Research

RSS

CytRx commences INNO-206 Phase 2 clinical trial for pancreatic cancer

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the initiation of a Phase 2 clinical trial evaluating the preliminary efficacy and safety of INNO-206 in patients with advanced pancreatic ductual adenocarcinomas (PDA) who have progressed after receiving two prior therapies.

26 Apr 2012

Gamma-linoleic acid can inhibit growth of pancreatic cancer cells

The dietary supplement gamma-linoleic acid can inhibit the growth of a subset of pancreatic cancer cells and selectively promote cancer cell death in mice, a Mayo Clinic study has found.

4 Apr 2012

Study shows how to defeat chemotherapy barrier in pancreatic cancer

Scientists at Fred Hutchinson Cancer Research Center and the Translational Genomics Research Institute (TGen) have discovered a literal 'break through' in pancreatic cancer.

21 Mar 2012

FHCRC research represents potential breakthrough in treatment of pancreas cancer

Pancreas cancer tumors spread quickly and are notoriously resistant to treatment, making them among the deadliest of malignancies. Their resistance to chemotherapy stems in part from a unique biological barrier the tumor builds around itself. Now scientists at Fred Hutchinson Cancer Research Center have found a way to break through that defense, and their research represents a potential breakthrough in the treatment of pancreas cancer.

20 Mar 2012

Scientists connect two signature characteristics of pancreatic cancer

Scientists have connected two signature characteristics of pancreatic cancer, identifying a self-perpetuating "vicious cycle" of molecular activity and a new potential target for drugs to treat one of the most lehal forms of cancer.

27 Jan 2012

Damon Runyon Cancer Research Foundation names 18 new Fellows

The Damon Runyon Cancer Research Foundation, a non-profit organization focused on supporting innovative early career researchers, named 18 new Damon Runyon Fellows at its fall Fellowship Award Committee review.

11 Jan 2012

Scientists identify key tumorigenic pathways in never-smoker lung adenocarcinoma patients

Researchers at the Translational Genomics Research Institute (TGen) have begun to identify mutations and cellular pathway changes that lead to lung cancer in never-smokers - a first step in developing potential therapeutic targets.

9 Jan 2012

Aurora kinase inhibitor may treat neuroendocrine prostate cancer

An international team of researchers led by clinicians at Weill Cornell Medical College have discovered a genetic Achilles' heel in an aggressive type of prostate cancer -- a vulnerability they say can be attacked by a targeted drug that is already in clinical trials to treat other types of cancers.

17 Nov 2011

New treatment may be on the horizon for neuroendocrine prostate cancers

A recent report in Cancer Discovery, a journal of the American Association for Cancer Research, suggests that a new treatment may be on the horizon for neuroendocrine prostate cancers, the most lethal subtype of this disease.

17 Nov 2011

RAZCER (Rapid Astrazeneca and CARO Evaluation of Radio-modifiers) awards announced - five Canadians win

Five leading Canadian radiation oncologists receive RAZCER Awards of $22,727 each for novel studies of radiation-drug interactions that have the potential to either protect normal tissues or sensitize tumours, and thus to enhance the effectiveness of radiation therapy for cancer patients. A selection committee of members of the Canadian Association of Radiation Oncology (CARO) selected the 2011 recipients from among a field of 12 applicants. Astrazeneca provides the funds for the RAZCER Award as an educational grant.

13 Oct 2011

First report of alternative lengthening of telomeres in human cancer subtypes

The first report of the presence of alternative lengthening of telomeres (ALT) in cancers arising from the bladder, cervix, endometrium, esophagus, gallbladder, liver, and lung was published today in The American Journal of Pathology. The presence of ALT in carcinomas can be used as a diagnostic marker and has implications for the development of anti-cancer drug therapies.

3 Sep 2011

Never smokers' lung adenocarcinomas show greater genome instability

Lung adenocarcinomas in people who have never smoked show greater genome instability than those in smokers, supporting the theory that lung cancer in never smokers arises through different pathways, according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer.

5 Jul 2011

Study traces precursor of deadly esophageal cancers to leftover embryonic cells

The ultimate source of some cancers is embryonic cells. Research published in the June 24th Cell, a Cell Press publication, traces the precursor of deadly esophageal cancers to leftover embryonic cells found in all adults.

24 Jun 2011

Response Genetics' clinical approaches to improve cancer care to be presented at ASCO 2011

Response Genetics, Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, announced today five presentations to be held during the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, IL from June 3 to June 7, 2011.

4 Jun 2011

AIDS people may face high risk of stomach and esophageal malignancies

Among people with AIDS, the risk of stomach and esophageal malignancies is higher than among the general population, according to study results presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.

5 Apr 2011

Researcher argues against use of Cop1-inhibitory drugs for cancer treatment

Jean-Christophe Marine strongly argues against the use of Cop1-inhibitory drugs. The protein Cop1 has -for a long time - been seen as an attractive drug target for cancer. But Jean-Christophe Marine found out that Cop1 acts as a tumor suppressor, and thus inhibits tumor formation. His new data will have direct implications for the development of cancer drug targets.

16 Mar 2011

Biocare, HJF sign license agreement to distribute antibody against prostate cancer

The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. has signed a licensing agreement with Biocare Medical, a biotechnology company based in Concord, Calif., for the exclusive worldwide sales and distribution rights for the immunohistochemistry of an antibody designed to detect tumor prevalence in prostate cancer patients.

18 Feb 2011

Epigenetic therapy holds promise for cancer management

Syndax, a clinical-stage epigenetics oncology company, announced publication of data of entinostat combined with the demethylating agent Vidaza® (azacitidine) showing effect in reducing tumor burden in differentiated tumor cells in animal tumor models of non-small cell lung cancer (NSCLC). The data is being published in the January 15, 2011 issue of Cancer Research.

12 Jan 2011

Nanoparticles may help diagnose and treat pancreatic and ovarian cancer

The research - carried out by a group of five institutions, including Einstein, that comprise the Texas Center for Cancer Nanomedicine - could lead to novel ways to diagnose and treat pancreatic and ovarian cancer using nanoparticles.

4 Jan 2011

Study finds invasive patterns of lung cancer in pediatric patients

Because primary lung adenocarcinoma is exceedingly rare in the pediatric population, it is difficult to properly classify certain lung tumors in children and adolescents. While anecdotal reports of pediatric patients with lung cancer lesions exist, little research has been conducted to link the disease in children to similar pulmonary malignancies in adults.

2 Nov 2010